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Summary 
The bd-2 protooncogene has been shown to provide a survival signal to self-reactive B ceils, but 
it fails to override their developmental arrest after encounter with antigen. Furthermore, con- 
stitutive expression of bcl-2 in B cells does not promote the development of autoimmune disease 
in most strains of mice, indicating that signals  other than those conferred by bcl-2 are required 
for long-term survival and differentiation of self-reactive B  cells in vivo. To further examine 
the factors that are required for the pathogenesis of autoimmune disease, we have assessed the 
effect of bd-2 overexpression on the development of host-versus-graft disease, a self-limited model 
of systemic autoimmune  disease.  In this  model,  injection  of spleen  cells  from (C57BL/6  ￿ 
BALB/c)F1  hybrid mice into BALB/c  newborn parental mice induces immunological toler- 
ance to donor tissues  and activation of autoreactive F 1 donor B  cells through interactions pro- 
vided by allogeneic  host  CD4 +  T  cells.  BALB/c  newborns  injected  with  spleen  cells  from 
(C57BL/6  ￿  BALB/c)F 1 mice expressing a bd-2 transgene in B  cells developed high levels of 
anti-single-stranded  DNA and  a  wide  range  of pathogenic  autoantibodies  that  were  not  or 
barely detectable in mice injected with nontransgenic spleen cells.  In mice injected with trans- 
genic B  cells,  the levels of pathogenic autoantibodies remained high during the course of the 
study and were associated with long-term persistence of donor B cells, development of a severe 
autoimmune disease,  and accelerated mortality. These results demonstrate that bcl-2  can pro- 
vide survival signals for the maintenance and differentiation of autoreactive B cells, and suggest 
that both increased B cell survival and T  cell help play critical roles in the development of cer- 
tain forms of systemic autoimmune disease. 
T 
he injection ofsemiallogeneic lymphoid cells into new- 
born parental  mice induces  immunological tolerance 
to  donor tissues  and  establishment of a B  and T  cell chi- 
merism (1,  2).  In addition, the injection of spleen ceils dif- 
feting at MHC class II molecules, but not at MHC class I or 
non-MHC alloantigens,  results in a lupuslike autoimmune 
syndrome  also  known  as  host-vs.-graft disease  (HVGD)  1 
(2-5). This syndrome is characterized by hypergammaglob- 
ulinemia, predominantly of the IgG1 and IgE isotypes (2), 
and the production of various autoantibodies (autoAbs), in- 
cluding anti-single-stranded (ss)DNA, antinuclear,  and an- 
ticytoskeleton autoAbs (2, 6). The autoAb response appears 
~Abbreviations used in this paper: ANCA, antineutrophil cytoplasm anti- 
body; anti-MPO, antimyeloperoxidase; anti-PR3, antiproteinase 3; au- 
toAb, autoantibody; CB6F,  (C57BL/6 ￿  BALB/c)F1; dsDNA, double- 
stranded DNA; gp70 IC:  gp70-anti-gp70 immune complex; HVGD: 
host-vs.-graft disease; ssDNA, single-stranded DNA; Tg  +, Ig-bcl-2 trans- 
genic; Tg-, Ig-bcl-2  nontransgenic. 
secondary to polyclonal activation of donor B  cells by tol- 
erance-resistant alloreactive host Th2 CD4 + T  cells  (7-10). 
However, autoAbs with known pathological consequences, 
such as anti-double-stranded (ds)DNA (11),  anti-gp70 (12), 
antilaminin  (13),  or these against antineutrophil  cytoplasm 
Ab components (ANCAs)  (14,  15),  are not found in mice 
injected at birth with F 1 cells. Another important feature of 
HVGD-associated autoimmune  syndrome  is  that  autoAb 
production is self-limited because of a rapid drop in B  cell 
chimerism by 10 wk of age (2,  16).  Indeed, reinjection of 
spleen cells induces a flare in the serological manifestations 
(16),  emphasizing the central role of donor B  cell chimer- 
ism in the  development and self-limitation of the  HVGD 
in tolerant mice. In addition to autoAb production, limited 
glomerular lesions are observed in these animals that totally 
disappear some weeks after the normalization of the sero- 
logical parameters (16). 
The proto-oncogene bd-2 was the first member of an ex- 
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way. A  role for bcl-2 in the selection ofB lymphocytes was 
suggested by its tightly regulated expression pattern during 
B cell development (17,  18). Bcl-2 was highly expressed in 
pro-B  and  mature  B  cells  but  downregulated  in  pre-B/ 
immature  cells,  stages  of development associated with ex- 
tensive  cell  death  and  clonal  selection.  Similarly,  the  ex- 
pression ofBcl-2 dechnes in B cells of the germinal center, a 
site associated with selection of B cells bearing high-afflnity 
Ig receptors for antigen (19, 20). Analysis of Bcl-2--deficient 
mice has demonstrated that Bcl-2 is essential for the main- 
tenance of mature T  and B lymphocytes (21, 22). In trans- 
genic mice, overexpression of bd-2 protected B cells against 
many  forms  of cell  death  (23,  24)  and,  in  some  genetic 
backgrounds  such  as  (C57BL/6  ￿  SJL/J)F1  mice,  pro- 
moted  the  development  of a  lupuslike  autoimmune  syn- 
drome (24). However, most strains of bd-2 transgenic mice 
failed to develop any sign of autoimmune disease  (23,  25), 
indicating that factors other than bd-2 are necessary for the 
development of systemic autoimmune disease. 
Here, we have evaluated the contribution of bcl-2 to the 
development ofautoimmune disease using the HVGD model, 
an established  experimental  system of a self-limited lupus- 
like  syndrome secondary to a  cognate allogeneic  T-B  cell 
interaction.  Our results demonstrate that BALB/c mice in- 
jected  with  spleen  cells  from  (C57BL/6  ￿  BALB/c)F1 
(CB6F1) mice overexpressing bcl-2 in B  cells,  but not with 
spleen cells from nontransgenic CB6F  1 controls, developed 
a chronic and lethal form of systemic lupuslike disease. De- 
velopment of autoimmunity correlated with the persistence 
of B  cell  chimerism  and  with  the  appearance  of a  broad 
spectrum of pathogenic autoAbs. These results indicate that 
disregulation  of apoptotic mechanisms in B  cells,  together 
with appropriate  T  cell help,  can be of paramount impor- 
tance in the pathogenesis of certains forms of autoimmune 
disease. 
Materials and Methods 
Mice.  BALB/c mice were purchased from CRIFFA (Barce- 
lona, Spain). C57BL/6-lg-bcl-2 transgenic mice (Tg  +) were kindly 
provided  by  Dr.  S.J. Korsmeyer  (Washington  University,  St. 
Louis, MO; 23). Tg  + or nontransgenic (Tg-) CB6F  1 hybrid mice 
were obtained by crossing BALB/c and C57BL/6-Ig-bcl-2 +/- 
heterozygous mice.  All mice were maintained  under pathogen- 
free conditions. 
Induction of Neonatal Tolerance.  Neonatal tolerance to H-2  bal- 
loantigens  was induced by i.p. injection of 0.7 ￿  108 spleen  cells 
from CB6F~-Tg  + hybrid mice or 108 spleen  cells from CB6F  1- 
Tg- into BALB/c mice within  the first 24 h  after birth,  as de- 
scribed  (2). These numbers were  chosen in order to inject  the 
same absolute number orB cells in both groups of mice, as deter- 
mined by flow cytometric analysis. The percentage of plasma cells 
in  donor  spleen  cells was  calculated  after  Giemsa  staining  of 
spleen cell smears. 
Flow CytometricAnalysis.  CB6F1-Tg  +  mice  were  identified 
by flow cytometry on PBLs  using the 6C8  mAb (20) (hamster 
anti-human  Bcl-2;  PharMingen,  San  Diego,  CA)  and biotiny- 
lated  F(ab')2  goat anti-hamster  IgG (Jackson  ImmunoResearch, 
West Grove, PA), as previously described  (17). To calculate  the 
number of B  cells in spleen  cell suspensions  from CB6F  1 mice, 
cells were  stained  with  FITC-conjugated rat  anti-mouse  B220 
mAb (clone RA3-6B2; PharMingen)  and analyzed  by flow cy- 
tometry. B cell chimerism in spleen  and peripheral  and mesen- 
teric  lymph nodes was assessed by flow cytometry using FITC- 
anti-B220 mAb and biotin-labeled mouse anti-mouse IA  b mAb 
(clone  KH74; PharMingen), followed by streptavidin-PE (Tago, 
Inc., Burhngame, CA). Cells were analyzed in a FACScan  |  flow 
cytometer using  Lysys  II  software  (Becton  Dickinson  &  Co., 
Mountain View, CA). Dead cells and debris were excluded based 
on forward and sideways light scatter. 
Serological Studies.  Serum levels of Ig bearing the donor Igh  b 
allotype in tolerant mice were assessed by ELISA as previously 
described  (2). Results were expressed as milligram equivalent per 
milliliter  of Ighb-bearing Ig relative  to that detected in the sera of 
age-matched normal C57BL/6 mice.  Serum levels of IgG anti- 
dsDNA and anti-ssDNA autoAbs were determined by ELISA as 
described  elsewhere  (2, 26). IgG anticytoskeleton Abs were eval- 
uated  by  ELISA as  described  previously  (6). Results  of anti- 
ssDNA, anti-dsDNA, and anti-cytoskeleton Abs were expressed 
in titration units referred  to a standard curve obtained by serial di- 
lutions of a serum pool obtained from 6-8-mo-old MRL lpr/Ipr 
mice. The presence of ANCA was evaluated  by indirect immu- 
no  fluorescence  on  slides coated  with  neutrophils  (Cormedica, 
Barcelona,  Spain)  using  a  1/20  dilution  of sera  followed  by 
FITC-conjugated rabbit anti-mouse IgG (DAKO, Glostrup,  Den- 
mark).  IgG  antiproteinase  3  (anti-PR3)  or  antimyeloperoxidase 
(anti-MPO)  specifities  of ANCA were  determined  by ELISA. 
Briefly,  100 I~1 of diluted serum (1:50) in 2% PBS/0.05% BSA/ 
Tween 20 were incubated for 2 h at room temperature in micro- 
titer wells previously coated with PR3 or MPO antigen  (Shield 
Diagnostics,  Dundee, England). After three washes, wells were in- 
cubated for 2 h at room temperature with 100 txl of alkaline phos- 
phatase-conjugated goat anti-mouse ~/chain-specific polyclonal 
Ab  (Sigma  Chemical  Co.,  St.  Louis,  MO;  1 Ixg/ml).  Results 
were expressed in units of absorbance  at 405 nm. Serum levels of 
gp70-anti-gp70 immune complexes (gp70  IC) were determined 
by ELISA as described  previously (27). R.esults were expressed  as 
nanograms of Ab-bound gp70 per milliliter  of serum.  Serum RF 
activity  was evaluated  by ELISA on microtiter wells coated with 
mouse-purified  mAb  of the  IgG1  or  IgG2a subclasses,  as  de- 
scribed  (27). 
Histological Studies.  Tissue samples from all major organs were 
fixed in 10% formaldehyde, imbedded in paraffin, and 3-~m sec- 
tions were processed for hematoxyhn-eosin staining, periodic acid- 
Schiff staining,  and silver-metenamin impregnation, according to 
standard  methods. Glomerular lesions were scored on a 0--4 scale 
based on the intensity and extent of histopathological changes  as 
described  previously (27). Deposition of IgM and IgG subclasses 
was  assessed by direct  immunofluorescence on  kidney  cryocut 
sections (4 b~m) using FITC-rabbit anti-mouse IgM (Cappel Lab- 
oratories,  Durham, NC)  or rabbit anti-mouse IgG subclass-spe- 
cific  antiserum  (Southern  Biotechnology Associates,  Birming- 
ham, AL). 
Statistical Analysis.  Statistical analysis was performed using the 
Wilcoxon two-sample test. Probability values >5% were consid- 
ered insignificant. 
Results 
Effects of a bcl-2 Transgene on the B  Cell Chimerism Associat- 
ed with Neonatal Injection ofF1 Spleen Cells.  To analyze whether 
2524  Bcl-2 Induces Systemic Lupuslike Disease in Mice Tolerized  to Alloantigens Table 1.  Evolution  of B Cell Chimerism in BALB/c Mice NeonataUy Injected with Semiallogeneic Spleen Cells  from CB6F1-Tg  + 
or CB6F1-Tg- Mice 
Percent IA  b+, B220 + cells/total B220 + cells 
Cells 
injected  Peripheral  Mesenteric 
at birth  Age  Spleen  lymph nodes  lymph nodes 
CB6F1-Tg- 
CB6F1-Tg  + 
5 d  2.3 (0.1)/11.6  47.7 (0.6)/55.7  37.0 (1.4)/42,7 
3 wk  3.3 (1.5)/30.0  2.9 (0.4)/19.6  3.0 (0,5)/12.5 
20 wk  1.6 (0.0)/50.0  0.9 (0.5)/22.0  ND 
5 d  2,8 (1.1)/18.4  43.7 (13.1)/57.1  27.7 (17,5)/40.1 
3 wk  4.3 (1.4)/33.1  6.0 (1.5)/42.9  5.4 (1.3)/26.6 
20 wE  20.7 (15.0)/43.2  3.0 (2.4)/45.5  4.1  (1.6)/36.0 
Spleen, peripheral, or mesenteric lymph node ceils were stained with FITC and-B220 mAb and biodn-anti-lA  b mAb, followed by streptavidin-PE. 
Results shown indicate the frequency of I-Ab  + B200 + cells in the total lymphoid population. Mean values and SD (in parentheses) are shown. The 
frequency of total B220 + cells is also indicated. Ikesults were calculated using five to eight mice in each group. 
constitutive expression of bcl-2 in donor B cells influences the 
development of HVGD in tolerant mice, newborn BALB/c 
mice (H-2  d) were injected intraperitoneally with 0.7  ￿  10  s 
spleen cells from CB6F1-Tg + or 10  s spleen cells from CB6F 1- 
Tg- littermates  (H-2  b/d) as controls.  The number of spleen 
cells was chosen in order to inject the same absolute num- 
ber of F 1 B  cells in both groups of mice since donor B  but 
not T  cells are essential for HVGD  development (2, 7-10). 
Flow  cytometric  studies  indicated  that  >98%  of the  in- 
jected  splenic  B  cells  from  CB6F1-Tg +  and  CB6F1-Tg- 
donors  were  small  IgM+B220 §  cells,  and  <0.5%  of the 
spleen  cells from both  groups  were  plasma cells  (data  not 
shown).  The establishment  of tolerance  to donor  alloanti- 
gens  was  analyzed by measuring  the  percentage  of donor 
I-A  b+  cells in spleen and lymph nodes of injected mice. A 
similar  percentage  of donor  I-A  b+  cells  was  observed  in 
spleen and lymph nodes of BALB/c recipients 5 d and 3 wk 
after injection  of either CB6F1-Tg + or CB6F1-Tg-  spleen 
cells  (Table  1).  By 20  wk after injection,  however,  donor 
I-A  b+  cells were  almost undetectable  in BALB/c  mice in- 
jected with  CB6F1-Tg-  spleen  cells.  In contrast,  the  per- 
centage  of donor  B  cells  in  BALB/c  mice  injected  with 
CB6F1-Tg + spleen cells remained high at 20 wk (Table 1). 
To further assess  the chimerism and activation of donor 
B  cells,  the  levels  of Ig bearing  donor  Igh  b allotype were 
analyzed in tolerant mice (2), An increase in the amount of 
Ig bearing  the  donor  Igh  b allotype  was  observed  in  both 
groups  of BALB/c  mice  neonatally  injected  with  CB6F 1 
spleen cells (Fig.  1). However, the levels of Igs bearing do- 
nor Igh  b allotype were 5-10 times higher in BALB/c mice 
injected  with  CB6FrTg +  spleen  cells than  in  the  control 
group  injected  with  CB6F1-Tg-  spleen  cells.  Moreover, 
BALB/c  mice  injected  with  CB6F1-Tg +  cells  exhibited 
Igh  b  allotype  levels  that  remained  elevated  at  least  until 
week  12 which  contrasted with  a  rapid  decrease  in serum 
Ig of donor  Igh  b allotype in mice receiving nontransgenic 
spleen cells (Fig.  1). 
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Mice Injected with Splenk B  Cells Overexpressing bcl-2 De- 
velop High and Sustained Levels of a Wide Range of AutoAbs. 
We  next  examined  the  production  of several  autoAbs  in 
BALB/c mice injected at birth with spleen cells from either 
CB6F1-Tg-  or  CB6F1-Tg +  mice.  As  previously reported 
(2, 28), animals injected with CB6FrTg-  spleen ceils pro- 
duced  increased  levels  of IgG anti-ssDNA  autoAbs  when 
compared with uninjected or CB6F1-Tg + mice (P <0.001), 
but low or undetectable levels of IgG anti-dsDNA autoAbs 
(Fig. 2 A). The kinetics of anti-ssDNA autoAb production 
in these animals was similar to that described for Igh  b pro- 
duction.  The levels were  maximum at 3-6 wk of age and 
returned to normal values by 12 wk of age. In contrast,  the 
titers of anti-ssDNA autoAb were two- to threefold higher 
in  BALB/c  mice  tolerized  with  CB6F1-Tg +  spleen  cells 
than in the control group and remained elevated during the 
entire  course  of the  study  (P <0.005  from week  6  to  20) 
(Fig. 2 A). In both groups of animals, IgG anti-ssDNA au- 
toAbs  were  predominantly  of the  IgG1  isotype  (data  not 
shown),  as previously described  in  this  model  (2,  8),  sug- 
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Figure 1.  Serum levels of donor 
Ig of the  Igh  b allotype. BALB/c 
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spleen cells from CB6F1-Tg  + mice  lk 
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C57BL/6 serum. Results represent 
l~!~__.~t  mean  +  1 SD Of8-19 miceper 
group. Significant differences were 
observed between  BALB/c  mice 
injected  with  spleen cells from 
CB6F1-Tg  + and CB6F1-Tg- mice 
3  6  9  12  (P <0.001  at 3 wk and P <0.05 at 
Age (weeks)  6, 9, and 12 wk). A 
B 
12  24 
lo  _  _  . 
~ 
0  J  J 
Age (weeks)  BALB/c  BALB/c  +  F1  Tg  +  +  Ft Tg" 
I1~_ i 
9wk  9wk  BALB/c  F1  Tg  +  control  control 
u~ 
8 
g 
30014001  ~0000]  I<ianti'actin  -------- ~ 5001"~"  I!l  700-3004001  6~176 .Igl/i~/i  anti-desmin  ~000016500~]  IgG anti-myosin I  400-1  II  I/$ /~" 
o',  ,  .  ,  o'9  .  , 
3  6  12  15 
900 -,  IgG anti-laminin 
1000 - 
700  q  /  800" 
600 q 
500 -I  600" 
400 -I 
300 "I  ~ 
400" 
200 -I  200" 
3  6  12  15 
3  6  12  15 
IgG anti-virnentin 
1200. 
looo 
800' 
600" 
-----.  400' 
200" 
r162  o.  3  6  12  15 
Age (weeks) 
3  6  12  15 
IgG anti-keratan sulfate 
i 
Figure 2.  Serum  levels of  anti-ssDNA, 
anti-dsDNA  (A), and  anticytoskeleton 
(B) autoAbs. BALB/c mice were neona- 
tally  injected  with spleen  cells from 
CB6FI_Tg+ (11) or from normal CB6F  F 
Tg- mice (0). Uninjected BALB/c (A) 
and CB6F~-Tg  + mice (O) were used as 
controls. Results are expressed in titra- 
tion units by reference to a serum pool 
from Ml:LL.lpr/lpr mice. Mean -+ 1 SD 
of 15-20 mice per group are represented. 
gesting that an interaction between host Th2 CD4 + T  and 
donor B  cells is also responsible  for autoAb production in 
mice injected  with  CB6F~-Tg  +  spleen  cells.  Interestingly, 
the injection of spleen cells from CB6F1-Tg  + mice was ac- 
companied by the  production  of high levels  of IgG anti- 
dsDNA autoAbs when compared with mice injected with 
CB6F1-Tg- spleen cells (P <0.001)  (Fig. 2 A). 
Since BALB/c mice injected with CB6F1-Tg  + spleen cells 
produced  increased  levels  of autoAbs,  which  were  unde- 
tectable  in animals  injected  with  CB6F1-Tg-  spleen  cells, 
the presence  of a wide spectrum  of autoAbs was analyzed 
in both groups of mice. Abnormal levels of antiaortic myo- 
sin, antismooth muscle actin, and antidesmin autoAbs were 
observed in  both  groups  of tolerized  mice,  but  the  levels 
were much higher in mice injected with CB6F1-Tg  §  cells 
(P <0.01  except  for IgG antidesmin  autoAbs  at  weeks  3 
and 6) (Fig. 2 B). Significantly, autoAbs reactive with vimen- 
tin,  keratan sulfate,  and laminin were found exclusively in 
BALB/c  mice  tolerized  with  CB6F1-Tg  +  spleen  cells 
(P <0.001)  (Fig. 2 B). 
Production of ANCA and circulating gp70 IC is associ- 
ated  with  accelerated  autoimmune  disease  in  humans  and 
mice  (12,  14,  15).  Indirect  immunofluorescence  on fixed 
neutrophils with sera from mice injected with CB6F1-Tg  + 
spleen  cells,  but  not with  sera  from animals  injected  with 
CB6F1-Tg- spleen cells, showed the typical cytoplasmic and 
perinuclear  staining  pattern  compatible  with  the  presence 
of ANCA (data not shown).  Significantly, mice neonatally 
injected with CB6F1-Tg  + spleen cells produced high levels 
of anti-MPO  and anti-PR3 ANCA, detectable by ELISA, 
at 6 and 12 wk of age (Fig. 3 A). In addition, these animals 
produced increased  levels  of gp70  IC  (Fig.  3  B).  In con- 
trast, animals injected with CB6F1-Tg- spleen cells showed 
limited  or undetectable  levels of anti-MPO,  anti-PR3  au- 
toAbs and gp70 IC  (Fig.  3, A  and  B).  Importantly,  unin- 
jected BALB/c mice and donor CB6F1-Tg  + mice failed to 
produce significant levels of these autoAbs  (Figs.  2  and 3), 
indicating that both the bcl-2 transgene and allogeneic fac- 
tors are required  for the  development of a wide spectrum 
ofautoAbs. Finally, we evaluated the presence ofanti-IgG1 
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Figure 3.  Serum levels of anti-MPO  and anti-PR3 ANCA (A) and 
nephritogenic anti-gp70 IC (B). (A) BALB/c mice were neonatally in- 
jected with spleen cells from CB6F1-Tg  + (m) or from normal CB6F  1- 
Tg- mice (0). Uninjected BALB/c (&) and CB6F1-Tg  + mice (O) were 
used as controls. Results are expressed in absorbance units at 405 nm. The 
production of IgG anti-MPO  ANCA between BALB/c mice injected 
with spleen cells from CB6F1-Tg  + and CB6F1-Tg- mice was statistically 
significant at 12 wk (P <0.001). In contrast, significant differences were 
observed in the levels of lgG anti-PR3 ANCA between both groups of 
mice during the entire course of the study (P <0.01). (B) gp70 IC levels 
were analyzed in 6- and  t2-wk-old  BALB/c mice neonatally injected 
with CB6F1-Tg  + or with CB6FrTg- spleen cells. 9-wk-old BALB/c 
and CB6F~-Tg  + mice were used as controls. Results are expressed in nan- 
ograms of Ab-bound gp70 per milliliter of serum. The differences be- 
tween BALB/c mice injected with spleen cells from CB6F~-Tg  + and 
CB6FI-Tg- mice were statistically significant (P <0.01 at 12 wk). 
and anti-IgG2a RF in sera from mice injected with CB6Fi 
spleen cells.  There was no increase in RF activity in either 
group  of mice  injected  with  F 1 cells  when  compared  to 
normal BALB/c mice (data not shown). 
BALB/c  Mice  Injected  with  CB6FI-Tg +  Spleen  Cells  De- 
velop  Severe  Autoimmune  Disease  and  Accelerated  Mortality. 
Unlike  BALB/c  mice  injected  at  birth  with  CB6F~-Tg- 
spleen  cells  that  remained  healthy and  survived,  >50%  of 
mice tolerized with CB6F1-Tg  + spleen cells  died before 20 
wk  of age  (Fig.  4).  Significantly,  the  highest incidence  of 
mortality coincided with the peak of ANCA and gp70 IC 
production ("~12 wk of age; Figs. 3 and 4). Histopatholog- 
ical  analysis  revealed  that  BALB/c  mice  injected  with 
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Figure 4.  Mortalit  3, curve of BALB/c mice injected at birth  with 
spleen cells from CB6F1-Tg  + mice (26 mice, thick line) or from normal 
CB6FI-Tg-  mice (16 mice, dashed line). Uninjected BALB/c (12 mice, 
thin line) and CB6FrTg  + mice (8 mice, dotted line) served as controls. 
CB6FrTg + spleen cells developed a severe form of diffuse 
proliferative  glomerulonephritis  characterized  by increased 
mesangial and glomerular cellularity,  obliteration  of glom- 
erular architecture, and tubular cast formation (Fig. 5, A  and 
C). Immunofluorescence studies demonstrated the presence 
of IgG and IgM deposits in the glomeruli of these mice (data 
not shown). In contrast, BALB/c mice injected with CB6Ft- 
Tg-  spleen  cells  exhibited  minimal  glomerular  changes 
(Fig.  5,  B  and  D).  In  addition,  animals  tolerized  with 
CB6F1-Tg  + spleen  cells developed interstitial  lymphocytic 
pneumonitis characterized by prominent peribronchial  (Fig. 
5  E)  and  perivascular  (data  not  shown)  accumulation  of 
mononuclear cells,  and marked lymphoid infiltrates  in the 
liver resembling  chronic active hepatitis  (Fig.  5  G).  None 
of these histological abnormalities was observed in BALB/c 
mice injected with CB6FrTg-  spleen cells  (Fig.  5,  F  and 
H). Despite the production of high levels ofanti-MPO and 
anti-PR.3 ANCA, BALB/c mice injected with CB6F1-Tg  + 
spleen  cells failed to develop typical lesions of vasculitis in 
small and medium vessels (data not shown). 
Discussion 
The  HVGD  that  develops in mice tolerized  at birth  to 
alloantigens appears to reflect the activation of autoreactive 
F1 donor B cells by tolerance-resistant host T  cells  (2, 7-10). 
We showed in the present report that injection ofsemiallo- 
geneic splenic B cells expressing a bd-2 transgene into new- 
born parental mice induces sustained production of a wide 
range of autoAbs and early death.  The death of these mice 
appears related to the development of a severe diffuse pro- 
liferative  glomerulonephritis,  although the contribution  of 
liver and lung disease cannot be excluded. This severe form 
of  systemic lupuslike disease markedly contrasts with the mild 
and self-limited  autoimmune reaction that occurs after in- 
jection of spleen cells from nontransgenic mice (1, 2, 16). 
Experimental work by several investigators has suggested 
that normal mice contain B  cells with autoreactive poten- 
tial in their peripheral lymphoid repertoire  (29-31).  How- 
ever, it is thought that such autoreactive B cells are not effi- 
ciently stimulated to produce autoAbs because of the absence 
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model,  donor  autoreactive  B  cells  are  thought  to  receive 
stimulatory signals from host helper T  cells (7-10).  For ex- 
ample, production ofautoAbs bearing the allotypic markers 
of the  F1  donor  are not observed in the  absence of CD4 + 
host  T  cells  (7)  or after treatment  with  anti-IL4 mAb  (8). 
The  mechanism  responsible  for  the  transient  course  of 
HVGD appears to be secondary to the progressive loss of B 
cell  chimerism  since  reinjection  of F 1  donor  B  cells  into 
neonatally  tolerized  animals  reactivates  the  autoimmune 
manifestations (16). Since bd-2 confers increased survival to 
B  cells, our findings together with previous results (24, 33) 
suggest that bd-2 promotes enhanced and sustained autoAb 
production by prolonging the life span of autoreactive ma- 
ture B  cells and plasma cells. This conclusion is particularly 
relevant  for B  cells  that  produce  certain  autoAbs  such  as 
anti-DNA, antiacfin, antidesmin, or antimyosin autoAbs since 
they were  secreted,  although  at lower levels, by nontrans- 
genic donor B  cells.  Thus,  these results argue that the lim- 
ited rife span  of potentially  autoreactive  B  cells is a  major 
safeguard against the development of certain types of auto- 
Abs and perhaps autoimmune disease. These findings are in 
accord with  those  by Strasser et al.  (24)  who  showed that 
(C57BL/6  ￿  SJL/J)F 1 mice  overexpressing  bcl-2 in  the  B 
cell  compartment  develop  a  lethal  lupuslike  syndrome. 
However,  no  such  abnormalities  were  observed  in  other 
strains of bd-2 transgenic mice including C57BL/6,  BALB/ 
c, CB6F1,  (C57BL/6  ￿  C3H)F1,  and  (SW1L/J  ￿  SJL/J)F1 
mice  (23,  25,  the  present  study,  and  Merino,  R.,  and  G. 
Nfifiez,  unpublished  results).  Together,  these  observations 
support  the  conclusion  that signals other than  disregulated 
B  cell survival are necessary for disease development.  In the 
current  report,  we  provide  evidence  that  T  cell  help  to- 
gether  with  constitutive  expression  of bcl-2 in  B  cells  are 
necessary for the production of pathogenic autoAbs and the 
development of systemic autoimmune disease. 
A  major observation  of the present  study was that mice 
injected with semiallogeneic B  cells from CB6F1-Tg + mice 
produced  high  levels  of certain  pathogenic  autoAbs.  In- 
deed,  several autoAbs  such as those  reactive with  dsDNA, 
MPO,  PR3,  laminin,  and gp70 self-antigens have been as- 
sociated with the development of autoimmune kidney dis- 
ease  in  humans  and  rodents  (11-15).  These  potentially 
pathogenic  autoAbs were almost exclusively found in chi- 
meric  mice  injected  with  F1  B  cells  expressing  the  bd-2 
transgene.  At  least  two  different  possibilities  may  explain 
these findings.  First, it is possible that spleen cells from nor- 
mal mice contain  B  cells or their precursors  which,  upon 
injection into parental mice, are capable of producing such 
pathogenic autoAbs. However, secretion of pathogenic au- 
toAbs  might  be  too  low  to  be  detected  by  the  current 
methodology.  In this  scenario,  bd-2 promotes  the  autoAb 
response and autoimmune disease by increasing the longev- 
ity of mature autoreactive B  cell clones. A nonexclusive al- 
ternative explanation is that production  of at least some of 
the pathogenic autoAbs may be suppressed in normal mice 
through  censoring mechanisms  that  operate  during  B  cell 
development. In this context, in vivo models ofclonal B cell 
deletion using transgenic mice expressing Ig receptors spe- 
cific for hen egg lysozyme (HEL) or surface erythrocyte an- 
tigens, have demonstrated that bd-2 can rescue self-reactive 
B cells from death during development or in peripheral tissues, 
respectively  (34,  35).  However,  in  the  anti-HEL  system, 
self-reactive B  cells overexpressing bcl-2 remained  arrested 
and failed to differentiate into mature long-rived B cells (34). 
In  the  HVGD  model,  B  cells  that  produce  anti-dsDNA, 
anti-MPO,  anti-PR3,  antilaminin,  or  anti-gp70  autoAb 
might  be  rescued  from death  by bd-2 overexpression  and 
allowed to expand and mature through signals provided by 
activated allospecific host  CD4 +  T  cells (7-10).  Together, 
our results demonstrate  that alteration  of programmed cell 
death  regulatory mechanisms in autoreactive B  cells in the 
presence of appropriate T  cell help can markedly potentiate 
the autoimmune process. 
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Figurr  5.  Histological analysis of20-wk-old BALB/c mice injected at birth with spleen cells from CB6FrTg + or CB6FI-Tg- mice. Representative 
histological appearance of kidney from mice injected with CB6FrTg + spleen cells showing the presence of a diffuse proliferative glomerulonephritis and 
tubular cast formation (￿  (A). High power view ofglomerulus from mice injected with CB6FrTg + spleen cells showing increased glomerular cellu- 
larity and obliteration of glomemlar architecture (￿  (C). Peribronchial infiltration of plasma cells in the lung of mice injected with CB6F1-Tg  + 
spleen cells (￿  (E). Marked lymphoid infiltration of portal tracts extending into the hepatic parenchyma and bridging necrosis in the liver of mice in- 
jected with CB6F1-Tg  + spleen cells (￿  (G). Normal histological appearance of kidney (B and D), lung (F), and liver (H) of mice injected with 
CB6F1-Tg- spleen cells (￿  and ￿  in D). 
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